Beacon Immune Tolerance (2024)

What we cover

Beacon Immune Tolerance covers all pharmaceutical interventions used to treat autoimmune diseases, autoinflammatory diseases, alloimmune diseases and allergies.

From small molecules to CAR T therapy, the module encapsulates all drugs and therapies within the immune-mediated disease space.

New data expansion:Deals and Companies. Gain unparalleled access to in-depth company profiles and the latest commercial deals. Monitor your competitors and opportunities as well as benchmark deals and evaluate potential partners. Learn more about Deals and Companies data by downloading thefactsheet.

How Beacon helps

Here are a few use cases that have benefitted our clients in accelerating their immune tolerance development programs:

• Search therapeutics in the immune-disease space across all stages of development so you can accurately benchmark your strategies against all existingimmune tolerance and immunomodulatory drugs, and investigate the novel technologies being used by competitors
• Drastically reduce manual research time spent looking through publications and conference abstracts for preclinical and clinical trial results by relying on our comprehensive collection of data which can be searched by a variety of options includingdelivery system, cell type, disease indications and much more.
• Stay on top of emerging trends and new players in the immune tolerance field withreal-time updates and alerts, as well as in-depth monthly reports curated by our analyst team.

How Beacon Immune Tolerance works

All Immune Tolerance pages will have unique data fields that will help speed up the research process. These data fields include:

• Autoantigen specificity
• Mechanism of Action
• Cell Source
• Cell Type
• Delivery System
• Editing Technology
• Target Organ/Cell
• Formulation

Our uniqueMilestonesfilter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the immune tolerance space.

How we target the data for immune tolerance

We house all publicly available sources of data updated with 24 – 48 hours of publicationproactively. Our sources cover (but are not limited to):

• Clinical trials registries
• Scientific journals and publications
• Company reports and presentations
• Press releases
• Conference reports and abstracts
• Government and regulatory organizations
• Newspapers and other media
• Patents

Covering all Antibody Drug Conjugates (ADCs), Small Molecule Drug Conjugates (SMDCs), Protein Drug Conjugates (PDCs), Immunotoxins and more

Find out more

Covering all genetically and non-genetically engineered allogeneic and autologous cell-based therapies across all disease indications

Find out more

Covering all Bi- and Multi-Specific Antibodies, Antibody Fragments, Augmented Antibodies and more

Find out more

Beacon Cancer Vaccineprovides the solution you need to master the prophylactic and therapeutic cancer vaccines field.

Find out more

Covering all Immune Checkpoint Combination Trials and Immune Checkpoint Modulators in development across 27 different checkpoint targets

Find out more

Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.

Find out more

Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.

Find out more

From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.

Find out more

Covering all pharmaceutical grade microbiome-based therapeutics across all disease indications – Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape.

Find out more

Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.

Find out more

Beacon TPD provides the solution you need to master the targeted protein degradation field.

Find out more